Finally, LGALS3BP appeared to be involved in resistance to 17-AAG (17-N-Allylamino-17- demethoxygeldanamycin), an HSP90 inhibitor tested in phase II/III clinical trials in lung cancer [29]. This evidence concerns the gene LGALS3BP and lung cancer.